BB Biotech AG/€BION
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About BB Biotech AG
BB Biotech AG is an investment company that focuses on investments in the biotechnology industry. The company is headquartered in Schaffhausen, Switzerland, and specializes in managing a portfolio primarily composed of companies involved in the development of innovative drugs and therapies. It seeks to capture growth opportunities in the biotech sector by investing in firms with cutting-edge scientific research and promising product pipelines. BB Biotech AG's investment strategy is informed by an in-depth analysis of market trends and scientific advancements, ensuring a dynamic and diversified portfolio. Its geographic footprint is primarily in Europe, with strategic investments in biotech firms globally.
- Ticker
- €BION
- Sector
- Finance
- Primary listing
- XGAT
- Employees
- 10
- Headquarters
- Küsnacht, Switzerland
BB Biotech AG Metrics
BasicAdvanced
€3.3B
2.78
€21.15
0.67
€2.46
4.18%
Price and volume
Market cap
€3.3B
Beta
0.67
52-week high
€60.90
52-week low
€44.00
Average daily volume
84K
Dividend rate
€2.46
Financial strength
Current ratio
86.518
Quick ratio
86.511
Dividend payout ratio (TTM)
11.53%
Profitability
Gross margin (TTM)
100.00%
Net profit margin (TTM)
97.46%
Operating margin (TTM)
96.19%
Effective tax rate (TTM)
0.01%
Revenue per employee (TTM)
€119,671,470
Management effectiveness
Return on assets (TTM)
23.68%
Return on equity (TTM)
38.68%
Valuation
Price to earnings (TTM)
2.78
Price to revenue (TTM)
2.709
Price to book
0.93
Price to tangible book (TTM)
0.93
Price to free cash flow (TTM)
15.276
Free cash flow yield (TTM)
6.55%
Free cash flow per share (TTM)
3.849
Dividend yield (TTM)
4.18%
Forward dividend yield
4.18%
Growth
Revenue change (TTM)
448.40%
Earnings per share change (TTM)
546.26%
3-year revenue growth (CAGR)
3,646.74%
10-year revenue growth (CAGR)
7.62%
3-year earnings per share growth (CAGR)
45.05%
10-year earnings per share growth (CAGR)
15.03%
3-year dividend per share growth (CAGR)
-7.58%
10-year dividend per share growth (CAGR)
-2.51%
Bulls say / Bears say
In Q2 2026, NAV rose 17.2% in CHF, beating the Nasdaq Biotechnology Index by 3.5 percentage points. This shows the portfolio can outperform when its stock selection and clinical milestones work in its favour. (Edison Group)
Three portfolio companies received US drug approvals in Q3, while Amgen and Argenx also reported positive Phase III results. These advances could strengthen the commercial potential of several holdings. (BB Biotech AG)
Five portfolio companies have been acquired in 2026, including two deals completed in Q3 that generated about CHF 280 million. The proceeds were reinvested across 12 new positions, showing how successful exits can create fresh investment capacity. (BB Biotech AG)
In Q3 2026, NAV rose 3.0% in EUR, well behind the Nasdaq Biotechnology Index’s 9.2% gain. The relative shortfall raises questions about whether BB Biotech can keep pace with the wider sector. (BB Biotech AG)
The shares traded at a 14.1% discount to NAV on 3 November 2026. That discount can persist or widen, leaving shareholders with weaker returns than the underlying portfolio delivers. (BB Biotech AG)
The company replaced its previous fixed dividend policy with a target yield of 3% to 5% from financial year 2026. The payout may therefore be lower than 5% and less predictable for investors seeking steady income. (BB Biotech AG)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
BB Biotech AG Financial Performance
Revenues and expenses
BB Biotech AG Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.